Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13621197 | 0.92 | KDM4E (0.50) | KDM4EALDH1A1P2RX4SIGMAR1EPHX2 | |
| SCHEMBL23173792 | 0.89 | SLC6A5 (0.42) | KDM4EALDH1A1P2RX4SIGMAR1 | |
| SCHEMBL14045744 | 0.88 | SSTR4 (0.40) | SSTR4LTA4H | |
| SCHEMBL18212271 | 0.88 | SSTR4 (0.40) | SSTR4LTA4H | |
| SCHEMBL2781055 | 0.88 | SSTR4 (0.40) | SSTR4LTA4H | |
| SCHEMBL15808570 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL21888400 | 0.80 | SIGMAR1 (0.46) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL2016562 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL508551 | 0.80 | ATM (0.45) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL27563117 | 0.80 | LTA4H (0.38) | KDM4EALDH1A1LTA4HEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | claimed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | claimed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | claimed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | claimed |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2020-04-09 | — | — | US | claimed |
| EP-3601245-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2020-02-05 | — | — | EP | claimed |
| WO-2018183411-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-04 | — | — | WO | claimed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | claimed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | claimed |
| WO-2012113103-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE S.A. (CH) | 2012-08-30 | — | — | WO | claimed |
| CN-102260263-A | Diphenylamine purine derivatives, and preparation method and medicinal application thereof | — | 2011-11-30 | — | — | CN | claimed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-1906166-A | Novel pyridine derivative and pyrimidine derivative (1) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906167-A | Novel pyridine derivative and pyrimidine derivative (2) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | KDM4E 4595/4885ALDH1A1 240/4885P2RX4 3097/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | KDM4E 4595/4885ALDH1A1 240/4885P2RX4 3097/4885 |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | KDM4E 4595/4885ALDH1A1 240/4885P2RX4 3097/4885 |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | KDM4E 2249/4885ALDH1A1 1448/4885P2RX4 84/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | KDM4E 385/4885ALDH1A1 1944/4885P2RX4 3136/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | KDM4E 1054/4885ALDH1A1 540/4885P2RX4 4765/4885 |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | DCUN1D2, CLN6, CAPNS1 | KDM4E 4008/4885ALDH1A1 2290/4885P2RX4 4426/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | KDM4E 3295/4885ALDH1A1 3910/4885P2RX4 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.